Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562637 | 0.84 | GCGR (0.44) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL8846697 | 0.83 | DHODH (0.40) | GCGR | |
| SCHEMBL7720729 | 0.77 | GCGR (0.86) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6747779 | 0.73 | GCGR (0.74) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL3445407 | 0.73 | GCGR (0.78) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6871563 | 0.73 | GCGR (0.74) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL6953288 | 0.72 | GCGR (1.00) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL8846243 | 0.72 | GCGR (0.45) | GCGR | |
| SCHEMBL3407031 | 0.70 | GCGR (0.69) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL15029058 | 0.69 | GCGR (0.73) | GCGRESR1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0705837-B1 | Preparation of 3-Oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES (JP) | 2002-08-07 | — | — | EP | claimed |
| US-5677455-A | Preparation of 3-oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1997-10-14 | — | — | US | claimed |
| EP-0705837-A2 | Preparation of 3-Oxy-5-oxo-6-heptenoic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1996-04-10 | — | — | EP | claimed |
| EP-2598484-B1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2016-06-29 | — | — | EP | disclosed |
| CN-103119022-B | For the preparation of the method for key intermediate of synthesis Statins or its pharmacologically acceptable salt | LEK PHARMACEUTICALS D.D. (SI) | 2016-01-06 | — | — | CN | disclosed |
| US-9085538-B2 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-07-21 | — | — | US | disclosed |
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-02-20 | — | — | US | disclosed |
| EP-2598484-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK Pharmaceuticals d.d. (SI) | 2013-06-05 | — | — | EP | disclosed |
| CN-103119022-A | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS | 2013-05-22 | — | — | CN | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051854-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, PCSK9, FAH | GCGR 2328/4885ESR1 4631/4885HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.